Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
REDUCE LAP-HF TRIAL II
NCT03088033 · View on ClinicalTrials.gov ↗
Study Summary
Multicenter, Prospective, Randomized Controlled, Blinded Trial, with a Non-implant Control group; 1:1 randomization.
Conditions Studied
Interventions
- DEVICE IASD System II implant
- OTHER intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
Study Locations (20)
Florida
- Holy Cross Hospital — Fort Lauderdale
- Sarasota Memorial Hospital — Sarasota
- Tallahassee Research Institute, Inc. — Tallahassee
- Cleveland Clinic Florida — Weston
California
- Scripps Clinic — La Jolla
- Kaiser Permanente San Diego — La Jolla
- Kaiser Permanente San Francisco Medical Center — San Francisco
Illinois
- Northwestern University — Chicago
- University of Chicago Medical Center — Chicago
- Evanston Northshore Healthcare — Evanston
Arizona
- Arizona Cardiovascular Research Center — Phoenix
- University of Arizona College of Medicine — Tucson
Louisiana
- Cardiovascular Institute of the South — Houma
- Ochsner Clinic Foundation — New Orleans
Massachusetts
- Tufts New England Medical Center — Boston
- Massachusetts General Hospital — Boston
Colorado
- South Denver Cardiology Associates — Littleton
Connecticut
- Yale University — New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 608 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2026-09 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03088033
The ClinicalTrials.gov registry entry for NCT03088033 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 608 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corvia Medical, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions — of which IASD System II implant is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03088033 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Florida, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03088033 about?
NCT03088033 is a clinical study titled "REDUCE LAP-HF TRIAL II". Multicenter, Prospective, Randomized Controlled, Blinded Trial, with a Non-implant Control group; 1:1 randomization.
What is the current status of trial NCT03088033?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 608 participants. The study started on 2017-06-01. Estimated completion is 2026-09.
What conditions does trial NCT03088033 study?
This clinical trial studies the following conditions: Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03088033?
The interventions under investigation include: IASD System II implant (DEVICE), intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03088033?
This trial is sponsored by Corvia Medical, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03088033 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.